FreeStyle Libre 3 and 3 Plus are continuous glucose monitoring devices indicated for the management of diabetes in patients aged 4 years and older.
Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found.
Abbott Laboratories (ABT) stock is down as the FDA classifies the company's recent recall of FreeStyle Libre 3 glucose ...
The Food and Drug Administration has identified a Class I recall of certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus Sensors by Abbott Diabetes Care due to incorrect glucose readings that are ...
Feb 4 (Reuters) - The U.S. Food and Drug Administration on Wednesday classified Abbott's recall of certain glucose monitoring ...
The City of El Paso Department of Public Health (DPH) is offering free A1C testing to the community on “Take Charge Tuesdays” to help prevent and manage ...
Abbott (NYSE:ABT) is facing an FDA warning letter alleging quality system regulation violations related to FreeStyle Libre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results